Bosh sahifaLCTX • NYSEAMERICAN
add
Lineage Cell Therapeutics Inc
0,58Â $
Dastlabki sotuv:(2,34%)-0,014
0,57Â $
Yopilgan:13-yan, 6:27:53 (GMT-5) · USD · NYSEAMERICAN · Ogohlantirish
Yopilish kursi
0,53Â $
Kunlik diapazon
0,51Â $ - 0,58Â $
Yillik diapazon
0,48Â $ - 1,61Â $
Bozor kapitalizatsiyasi
128,37Â mln USD
Oʻrtacha hajm
3,17Â mln
Narx/foyda
-
Dividend daromadliligi
-
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 3,78Â mln | 203,29% |
Joriy xarajat | 4,41Â mln | 9,13% |
Sof foyda | -3,03Â mln | 57,33% |
Sof foyda marjasi | -80,29 | 85,93% |
Har bir ulushga tushum | -0,02 | 50,37% |
EBITDA | -3,70Â mln | 43,35% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 32,71Â mln | -20,86% |
Jami aktivlari | 96,59Â mln | -9,00% |
Jami passivlari | 31,80Â mln | -19,48% |
Umumiy kapital | 64,79 mln | — |
Tarqatilgan aksiyalar | 188,84 mln | — |
Narxi/balansdagi bahosi | 1,52 | — |
Aktivlardan daromad | -9,63% | — |
Kapitaldan daromad | -13,98% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | -3,03Â mln | 57,33% |
Operatsiyalardan naqd pul | -5,79Â mln | -14,89% |
Sarmoyadan naqd pul | 3,89Â mln | 83,22% |
Moliyadan naqd pul | -3,00Â ming | -100,37% |
Naqd pulning sof oʻzgarishi | -1,86 mln | 23,86% |
Boʻsh pul | -2,27 mln | 12,27% |
Haqida
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Tashkil etilgan
1990
Sayt
Xodimlar soni
72